European Patent Office

T 1411/23 (Regimen for HDM2-p53 interaction inhibitors / NOVARTIS) of 13.05.2025

European Case Law Identifier
ECLI:EP:BA:2025:T141123.20250513
Date of decision
13 May 2025
Case number
T 1411/23
Online on
10 July 2025
Petition for review of
-
Application number
17804304.8
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
DOSE AND REGIMEN FOR HDM2-P53 INTERACTION INHIBITORS
Applicant name
Novartis AG
Opponent name
STRAWMAN LIMITED
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Board
3.3.07
Headnote
-
Relevant legal provisions
European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 012(6)Rules of procedure of the Boards of Appeal 2020 Art 013(1)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
Keywords
Late-filed evidence - admittance of documents filed in appeal proceedings
Inventive step - main request and auxiliary requests 1 to 7 (no)
Catchword
-
Cited cases
-
Citing cases
-

Order

For these reasons it is decided that:

The appeal is dismissed.